ISPOR EUROPE 2024
November 17-20, 2024 | Barcelona, Spain
Generating Evidence for Health and Well-Being with Real-World Data
Book a Meeting
Visit Booth #407
Posters
Empowering Health Decisions with Real-World Data: Advancing Evidence for a Healthier Future
At ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2024—TriNetX is at the forefront of discussions around joint clinical assessments, real-world data, healthcare value, patient-centered research, and digital transformation in healthcare. Join us to discover how our solutions are enabling better clinical decisions, streamlining regulatory processes, and advancing global health outcomes.
Discover the latest in real-world data and clinical trial innovations from TriNetX. We are committed to helping researchers, clinicians, and decision-makers unlock new insights from health data to enhance health and well-being worldwide.
Pre-Book Meetings with TriNetX
Our team of experts will be onsite at ISPOR Europe to discuss how TriNetX’s real-world data solutions can drive impactful health research and better health outcomes. Visit us at our booth to connect!
Meet the TriNetX Experts at ISPOR Europe, Booth #407
TriNetX ISPOR Europe, Booth #407
Exhibit Hall Hours:
- Monday, November 18, 9:30-19:00 hours (9:30 AM – 7:00 PM)
- Tuesday, November 19, 9:30-19:00 hours (9:30 AM – 7:00 PM)
- Wednesday, November 20, 8:30-11:30 hours (8:30 AM – 11:30 AM)
Visit us at Booth #407 to discuss how TriNetX can support your research.
Meet TriNetX RWD Experts
Jeffrey Brown, PhD
Chief Scientific Officer, TriNetX
With more than 25 years of experience in research and consulting, Jeffrey Brown, PhD, is an internationally recognized expert in the use of real-world data (RWD) to support the evidentiary needs of regulatory agencies and medical product sponsors and an expert in the assessment of data quality of RWD resources.
Andreas Weber
Senior Vice President, TriNetX Oncology
As a senior executive with a proven track record in management and leadership, Andreas is known for his deep understanding of life sciences, spanning the entire industry continuum. His expertise encompasses pharmacovigilance, drug safety, regulatory affairs, and end-to-end eClinical processes, with a strong focus on business process optimization, outsourcing, and information technology.
ISPOR Europe Poster Presentations by TriNetX Real-World Data Experts
We are excited to present two posters at ISPOR Europe 2024, highlighting the latest findings from our real-world data. Visit our poster sessions to dive deeper into how TriNetX is transforming healthcare research.
Make all other accordions closed by default
custom CSS added to this menu item:
selector {
display: none;
}Poster CO19 — Comparative Analysis of Health Outcomes in Gestational Diabetes Mellitus: Diet-Controlled Vs. Insulin/Hypoglycemic-Controlled Methods
- TriNetX Authors: Kayla Delano and Isatu Kargbo
- Poster Session 1
- Date: Monday, November 18, 2024
- Poster Session Time: 10:30:00 AM – 1:30:00 PM
- Discussion Period: 12:30:00 PM – 1:30:00 PM
Patients with GDM managed with insulin or hypoglycemics exhibited higher risks of developing type 2 diabetes, pre-eclampsia, and requiring cesarean sections than those managed by diet alone. Given the results between the two cohorts, it may be beneficial for physicians to have a patient-centric focus while presenting options regarding prenatal care and labor and delivery options that are also cost-effective and less burdensome.
“In the matched analysis (N=26,905), the incidence of type 2 diabetes post-GDM was markedly higher in the insulin/hypoglycemic-controlled cohort (18.79%) compared to the diet-controlled cohort (3.97%, RR=0.212). Similar trends were observed for risks of pre-eclampsia (9.18% v. 5.73%, RR=0.624) and cesarean section (28.29% v. 22.19%, RR=0.784), with the insulin/hypoglycemic-controlled cohort showing higher risks.”
Poster RWD114 — Diagnostic Differences of Hearing Loss and Central Auditory Processing Disorder Following Varying Frequency of Temporary Auditory Threshold Shift on a Global Scale: A Comparative, Retrospective Real-World Data Analysis
- TriNetX Author: Tessa Sagarino
- Poster Session 3
- Date: Tuesday, November 19, 2024
- Poster Session Time: 10:30:00 AM – 1:30:00 PM
- Discussion Period: 12:30:00 PM – 1:30:00 PM
This poster explores the diagnostic differences in hearing loss and Central Auditory Processing Disorder (CAPD) in patients experiencing Temporary Auditory Threshold Shift (TATS). Utilizing real-world data from the TriNetX Global network, the study reveals that patients with recurrent TATS (rTATS) are significantly more likely to develop hearing loss or CAPD compared to those with a single occurrence of TATS. These findings highlight the risks of frequent exposure to high volume levels, such as loud music or traumatic events, and their long-term impact on auditory health. The results offer valuable insights into understanding the development of CAPD and the broader effects of noise-induced hearing loss globally.
TriNetX Real-World Data Resources
Explore our curated collection of high-quality resources tailored to support researchers, clinical trial professionals, and industry leaders in advancing health outcomes through evidence generation.
Blog:
The Future of Oncology Research in Europe: Integrating Real-World Evidence into Joint Clinical Assessments
Explore how real-world evidence (RWE) is transforming oncology research across Europe. This blog discusses the integration of RWE into joint clinical assessments and its potential to drive more efficient, inclusive, and impactful cancer research.
Webinar:
RWD to the Rescue – Solving R&D Challenges for Pharma Companies
How can real-world data (RWD) address the pressing challenges in R&D for pharma companies? Join our upcoming webinar to explore how RWD can revolutionize clinical research and help drive better decision-making throughout the drug development process.
Video:
Is Your Real-World Data Research-Ready? Optimizing Data Quality in Pharmacoepidemiologic Studies
With increasing use of real-world data (RWD) throughout the drug development cycle — from initial discovery through to market approval and post-market monitoring — comes increasing scrutiny about the quality of the data. Jeffrey Brown, PhD and Matvey Palchuk, MD, MS, FAMIA discuss the rise of RWD and its role in revolutionizing healthcare research and how the TriNetX team approaches data quality to ensure research-ready RWD.
Let’s Talk
Reserve your time with TriNetX experts live at ISPOR. Space is limited.
Our Mission
Our mission is to build a global data and analytics ecosystem that provides real-world insights to address the most pressing health challenges. This mission resonates beyond the walls of our organization, echoing in the corridors of our esteemed health care and industry partners. Every decision, innovation, and feature is fueled by our unwavering dedication to positively connect the world to improve human health.
Going Beyond What's Possible
As a global force, TriNetX continues to navigate uncharted territories with an unwavering commitment to revolutionizing the healthcare ecosystem.
Far beyond being a repository of information, TriNetX serves as a strategic partner in connecting health systems, providers, and researchers worldwide through our extensive real-world patient data that runs a mile wide and a mile deep.
From trial operations to evidence generation, we put you at the forefront of discovery.
Clinical Trial Design & Optimization
Data Sets & Analytics
Non-US Oncology
Real-World Evidence Generation
Pharmacovigilance & Drug Safety
Book a Meeting at ISPOR EU
Please complete the below to request a meeting at the ISPOR Europe in Barcelona, Spain this November 17-20, 2024.
Complete the form below to access a sample TriNetX Oncology GmbH TherapyMonitor Report:
"*" indicates required fields